[1]陈剑明△ 徐丁 汪帅伊 黄善昭 王娜.恒古骨伤愈合剂治疗绝经后骨质疏松症的临床研究[J].中国中医骨伤科杂志,2020,28(08):46-49.
　CHEN Jianming XU Ding WANG Shuaiyi HUANG Shanzhao WANG Na.Clinical Study of the Osteoking in Treating Postmenopausal Osteoporosis[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2020,28(08):46-49.
点击复制

恒古骨伤愈合剂治疗绝经后骨质疏松症的临床研究()
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第28卷
期数:
2020年08期
页码:
46-49
栏目:
临床研究
出版日期:
2020-08-10

文章信息/Info

Title:
Clinical Study of the Osteoking in Treating Postmenopausal Osteoporosis
文章编号:
1005-0205(2020)08-0046-04
作者:
陈剑明1△ 徐丁1 汪帅伊1 黄善昭1 王娜1
1浙江宁波市第六医院(浙江 宁波,315040)
Author(s):
CHEN Jianming1△ XU Ding1 WANG Shuaiyi1 HUANG Shanzhao1 WANG Na1
1Ningbo No.6 Hospital,Ningbo 315040,Zhejiang China.
关键词:
恒古骨伤愈合剂;  绝经后骨质疏松症;  骨密度
Keywords:
osteoking;  postmenopausal osteoporosis;  bone mineral density
分类号:
R681
文献标志码:
A
摘要:
目的:探讨并分析恒古骨伤愈合剂治疗绝经后骨质疏松症(PMOP)临床疗效及安全性。方法:选取2017年6月至2018年6月本院收治的206例PMOP患者为研究对象,采用随机数字表法分为治疗组(103例)和对照组(103例)。对照组给予碳酸钙D3片和阿法骨化醇软胶囊治疗; 治疗组在对照组基础上给予恒古骨伤愈合剂治疗,两组均连续治疗12个月。比较两组治疗效果,治疗前后骨密度(BMD)、血清骨代谢指标、安全性指标及不良反应。结果:治疗组治疗总有效率为89.32%,对照组治疗总有效率76.69%,两组差异有统计学意义(P<0.05); 治疗后两组骨密度(BMD)及血清Ⅰ型前胶原N端前肽(PINP)均明显高于治疗前,血清Ⅰ型胶原羧基末端肽(β-CTX)明显低于治疗前,差异有统计学意义(P<0.05); 且治疗组BMD,PINP,β-CTX改善程度均优于对照组,差异有统计学意义(P<0.05)。两组安全性指标差异无统计学意义(P>0.05),两组治疗期间不良反应发生率差异无统计学意义(P>0.05)。结论:恒古骨伤愈合剂治疗PMOP临床疗效显著,能有效提高骨密度,升高血清PINP水平,降低β-CTX水平,且不影响肝肾功能,未明显增加不良反应发生率。
Abstract:
Objective:To study the clinical effect and safety of osteoking in treating postmenopausal osteoporosis(PMOP).Methods:206 PMOP patients admitted to our hospital from June 2017 to June 2018 were randomly divided into treatment group(103 cases)and control group(103 cases).The former were treated with calcium carbonate D3 tablets and alfacalcidol soft capsules,while the treatment group added osteoking on the basis of the control group.Both groups were continuously treated for 12 months.The curative effect,bone mineral density(BMD),serum bone metabolism indexes,security indexes and adverse reactions were recorded.Results:The overall effective rate in the treatment group was higher than that in the control group(89.32% vs 76.69%,P<0.05).The BMD and serum type Ⅰ procollagen amino terminal peptide(PINP)levels in both groups were increased significantly and the serum type Ⅰ collagen carboxyl terminal peptide(β-CTX)levels were decreased significantly after treatment(P<0.05),while better changes in BMD,PINP and β-CTX were observe in treatment group(P<0.05).No significant changes in security index or adverse reactions were found between the two groups after treatment(P>0.05).Conclusion:Osteoking is markedly effective on the treatment of PMOP.It can effectively improve the BMD,increase serum PINP levels,and reduce β-CTX levels without affecting the liver and kidney function or significantly increasing the incidence of side effects.

参考文献/References:

[1] 赵敏,何承建.骨填充网袋治疗骨质疏松性椎体骨折不愈合的疗效观察[J].中国中医骨伤科杂志,2019,27(12):74-75.
[2] MCCLUNG M R.Drug holidays in women treated for postmenopausal osteoporosis[J].Menopause,2018,25(10):1152-1154.
[3] 李沛,潘富伟.骨质疏松症中医证候分布规律及相关性研究进展[J].中国骨质疏松杂志,2014,22(1):110-114.
[4] 吴超,唐薇,赵宏斌,等.恒古骨伤愈合剂对骨折树鼩血液生理和脏器系数的影响[J].中国比较医学杂志,2017,27(11):1-5.
[5] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊治指南(2011年)[J].中华骨质疏松和骨矿盐疾病杂志,2011,4(1):2-17.
[6] WADE S W,STRADER C,FITZPATRICK L A,et al.Estimating prevalence of osteoporosis:examples from industrialized countries[J].Arch Osteoporos,2014,9(1):182-208.
[7] 龚戬芳,郑舟军,余晓明,等.4 297例浙江省中老年人骨质疏松患病率及骨密度SOS值参考范围的调查研究[J].现代预防医学,2015,42(23):104-106.
[8] CRAMER J A,GOLD D T,SILVERMAN S L,et al.A systematic review of persistence and compliance with bisphosphonates for osteoporosis[J].Osteoporos Int,2017,18(8):1023-1031.
[9] 李中万,杨广钢,姚丽云,等.健肾方联合唑来膦酸治疗绝经后骨质疏松的临床观察[J].中国中医骨伤科杂志,2018,26(7):25-28.
[10] 李颖,姜志强,黄宏兴,等.补肾健脾中药复方预防椎体成形术后再骨折的随访研究[J].中国骨质疏松杂志,2017,23(5):667-671.
[11] 袁鑫,角建林,吴超,等.恒古骨伤愈合剂对绝经后骨质疏松和骨质疏松性骨折模型树鼩体成分的影响[J].中国药房,2018,29(18):28-31.
[12] 罗德军,赵宏斌,周旭,等.鲑鱼降钙素联合恒古骨伤愈合剂治疗腰椎OPF疗效分析[J].中华内分泌外科杂志,2011,5(3):158-160.
[13] 罗标.恒古骨伤愈颗粒薄层鉴别方法研究[J].河北中医,2010,32(8):1226-1226.
[14] 唐颂军,宋力轶,朱文峰,等.骨转换标志物PINP和β-CTX的测定在预测骨质疏松性骨折中的价值[J].实用临床医药杂志,2015,19(21):17-19.
[15] TROY K L,MANCUSO M E,JOHNSON J E,et al.Bone adaptation in adult women is related to loading dose:A 12-month randomized controlled trial[J].J Bone Miner Res,2020.doi:10.1002/jbmr.3999.
[16] 丁柱,朱兆洪,李国岩.骨密度测量诊断骨质疏松研究概况[J].中国中医骨伤科杂志,2004,12(3):46-49.
[17] FAZMIN I T,HUANG CL-H,JEEVARATNAM K.Bisphosphonates and a trial fibrillation:revisiting the controversy[J].Ann N Y Acad Sci,2020.doi:10.1111/nyas.14332.

备注/Memo

备注/Memo:
(收稿日期:2020-01-12)基金项目:浙江省卫生厅科研基金(2018KY722) △通信作者 E-mail:cjmdn01710@163.com
更新日期/Last Update: 2020-08-10